Fresenius Challenges Patents To Launch IBD Drug Biosimilar
Fresenius has urged a London judge to revoke three patents of its rival Millennium covering a popular treatment for inflammatory bowel disease, arguing that its dosing regimen and ingredients were nothing...To view the full article, register now.
Already a subscriber? Click here to view full article